Nicox shares soar on Zerviate OK; Gemphire CEO resigns; Array, Ono team up on a $187M deal
→ Nicox’s Zerviate received FDA approval today and $COX stocks have soared in response to the announcement. The company previously ran into trouble when a drug it out-licensed to Bausch + Lomb was delayed due to inadequacies at the company’s manufacturing facility. “Receiving approval from the U.S. FDA for Zerviate is a huge milestone for Nicox and partnering discussions are underway for U.S. commercialization rights,” commented Michele Garufi, the CEO of Nicox. Shares are up more than 20%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.